A expressão CD30 é uma característica definidora do linfoma anaplásico de grandes células (ALCL);...
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | BMA-CD30-ALCL |
|---|---|
| Tipo | Relevância terapêutica |
| Estado | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Doenças | DIS-ALCL |
| Fontes | SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Fatos de ação
| Biomarcador | BIO-CD30-IHC |
|---|---|
| Variante | CD30 expression — universal (~100%) in systemic anaplastic large-cell lymphoma (ALK-positive and ALK-negative) |
| Doença | DIS-ALCL |
| Nível ESCAT | IA |
| Combinações recomendadas | BV + CHP — 1L de SALCL por SRC-NCCN-BCELL-2025, SRC-ESMO-PTCL-2024, BV em monoterapia — R/R de resgate de SALCL por SRC-NCCN-BCELL-2025, HCT autólogo consolidado em CR1 (subgrupos de alto risco por SRC-NCCN-BCELL-2025) |
| Contraindicated monotherapy | BV + bleomycin (pulmonary toxicity contraindication), CHOP without BV in CD30+ PTCL with adequate CD30 expression (inferior per SRC-ECHELON-2-HORWITZ-2019) |
| Resumo das provas | CD30 expression is a defining feature of anaplastic large-cell lymphoma (sALCL); brentuximab vedotin (BV) targets CD30 with an auristatin payload. 1L sALCL: BV + CHP (cyclophosphamide / doxorubicin / prednisone, replacing vincristine) is preferred over CHOP per ECHELON-2 (Horwitz Lancet 2019 — mPFS 48 vs 21 mo, HR 0.71; OS HR 0.66) per SRC-NCCN-BCELL-2025, SRC-ESMO-PTCL-2024. R/R sALCL: BV monotherapy was the basis of FDA accelerated approval (Pro JCO 2012 — ORR 86%, CR 57%) and is preferred salvage. Pediatric ALCL: AHOD1331 supports BV + AVEPC. |
Notas
ESCAT IA / OncoKB Level 1. Existing BMA-ALK-FUSION-ALCL covers ALK- rearranged subset (where crizotinib R/R has different role). For sALCL, BV+CHP is genotype-agnostic 1L (covers ALK-positive and ALK- negative). ECHELON-2 enrolled CD30+ PTCL with ≥10% expression — that threshold is the standard inclusion gate. Bibliographic record SRC-ECHELON-2-HORWITZ-2019 is available; SRC-AHOD1331 remains a source gap and claim-level linkage requires clinical sign-off.
Usado por
Não há referências reversas encontradas no corpus YAML.